ImCheck Therapeutics is driving innovation in immune system modulation based on our unique know-how in the butyrophilin (BTN) and BTN-like (BTNL) superfamily of checkpoint molecules. We are designing the next generation of immunotherapeutic antibodies for the treatment of cancer, infectious disease, and autoimmune disease.
ImCheck To Present Data From the EVICTION-2 Study of ICT01 in Combination With IL-2 In Patients with Advanced Solid Tumors at AACR
Science & MedicineRead more
ImCheck Therapeutics is proud to be part of the FT120 for the fourth year in a row!
Leadership & CorporateRead more
STAY IN TOUCH WITH OUR LATEST NEWS
Subscribe to receive our press releases and related news